Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963611 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT01963611: Clinical Trial Phase 2 study, sponsored by EMD Serono.
NCT01963611 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 255 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01963611, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duration of 40 weeks.
Primary Outcome
Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions per Subject and Scan was calculated using 5 serial magnetic resonance imaging (MRI) scans.
Interventions
- DRUG Plovamer acetate 0.5 milligram (mg)
- DRUG Copaxone 20 mg
- DRUG Plovamer acetate 3 mg
- DRUG Plovamer acetate 10 mg
- DRUG Plovamer acetate 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Why NCT01963611 stopped before completion
NCT01963611 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 5 interventions - of which Plovamer acetate 0.5 milligram (mg) is the first listed.
NCT01963611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01963611 about?
NCT01963611 is a clinical study titled "Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)". This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duratio...
What is the current status of trial NCT01963611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2013-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01963611?
The interventions under investigation include: Plovamer acetate 0.5 milligram (mg) (DRUG), Copaxone 20 mg (DRUG), Plovamer acetate 3 mg (DRUG), Plovamer acetate 10 mg (DRUG), Plovamer acetate 20 mg (DRUG).
Who is sponsoring clinical trial NCT01963611?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01963611's enrollment target sits among peer trials
255 218th of 2000 higher than 1,782 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia